Milestone reports Q3 net loss of $9.4M; PDUFA for CARDAMYST set for March 27, 2025

Milestone Pharmaceuticals Inc.

2024-Q3 EPS reported -$0.48

PDUFA target date for CARDAMYST (etripamil) in PSVT is March 27, 2025.
China Phase 3 met primary endpoint: 40.5% conversion vs 15.9% placebo within 30 min (HR=3.00, p<0.001).
Phase 3 trial in AFib-RVR expected to start H1 2025 with repeat-dose 70 mg regimen.
Cash, equivalents and short-term investments $76.4M at Sep 30, 2024, up from $66.0M at Dec 31, 2023.
Net loss narrowed to $9.4M in Q3 2024 vs $15.1M in Q3 2023; R&D expense $4.0M vs $6.7M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.